Wednesday, February 04, 2026 ENC.1 (NRG GY018) overall survival and exploratory analysesOverall survival and exploratory analyses of the ENC1 (NRG GY018) phase 3 randomized trial. Findings further support the use of pembrolizumab plus chemotherapy as first-line treatment for patients with advanced stage or recurrent endometrial cancer regardless of mismatch repair status.Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel RS, Shahin MS, Cantuaria GH, Girda E, Lokich E, Kavecansky J, Leath CA, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O’Cearbhaill RE, Baghdadi TA, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nature Medicine 31: 1539-1546. 2025.https://doi.org/10.1038/s41591-025-03566-1 Secondary analysis of the LY.12 clinical trialGong IY, Kuruvilla J, Prica A, Olney HJ, Fraser GA, Buckstein RJ, Skrabek P, Keating M-M, Hay AE, Shepherd L, Chen BE, Crump M. Primary refractory disease in large B cell lymphoma: definition and outcomes from a secondary analysis of the LY.12 clinical trial. Letter to Editor. Blood Advances January 2026. p. 2025018491.https://doi.org/10.1182/bloodadvances.2025018491
